OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.
0.0079
8.14%
0.09 / 0.1049 (1 x 1)
KRTL Holding Group Inc. (OTC: KRTL) today announced that its wholly owned subsidiary, KRTL Biotech Inc., has secured an initial purchase order valued at $240,000 for Thiamine Mononitrate (Vitamin B1) and Riboflavin (Vitamin B2) through the efforts of its recently expanded sales leadership team. This order represents a strategic advancement in KRTL Biotech's expansion into the active pharmaceutical ingredient (API) sector—an industry fundamental to healthcare, wellness, and global pharmaceutical production.
The initial purchase order is currently advancing through internal processing stages, including standard procurement, quality control, and documentation review. While the Company is not in a position to confirm completion until all fulfillment steps are finalized, this milestone reflects a significant movement within KRTL Biotech’s expanding commercial operations. The Company remains committed to proceeding in full compliance with applicable laws and regulatory frameworks, while maintaining internal standards for transparency, quality assurance, and professional conduct throughout the transaction lifecycle.
This order serves as a meaningful validation of KRTL Biotech’s commercial positioning and supply readiness, with emphasis on sourcing high-purity, pharmaceutical-grade vitamins. KRTL Biotech continues to strengthen its access to secure supply chain channels, capable of supporting both domestic and international client demands. These developments enhance KRTL Biotech’s capabilities in traceability, regulatory documentation, and ingredient integrity, key metrics within the pharmaceutical and nutraceutical sectors.
"Obtaining this purchase order marks a significant step forward for KRTL Biotech," said Rick Haxton, Global Sales Director of KRTL Biotech. "It reflects the strength of our sales and sourcing model, our focus on quality, and the confidence that clients place in our execution. This milestone represents the beginning of a broader market engagement strategy aimed at scaling responsibly and compliantly."
The purchase order is expected to contribute to KRTL Biotech’s 2025 growth initiatives and further establish its profile as a reliable and compliant supplier in the global API and nutraceutical supply ecosystem.
About KRTL Holding Group Inc.
KRTL Holding Group Inc. (OTC: KRTL) operates through its wholly owned subsidiaries, KRTL Biotech Inc. and KRTL International Corp. The Company leverages strategic synergies across industries to pursue investments, mergers, and partnerships that deliver shareholder value. Focused on biotech, technology, and emerging market opportunities, KRTL Holding Group is committed to growth, innovation, and operational excellence.
About KRTL Biotech Inc.
KRTL Biotech Inc., a wholly owned subsidiary of KRTL Holding Group Inc., specializes in pharmaceutical registration, regulatory compliance, and FDA services for both international and domestic clients. The company plays a pivotal role in product registration and importation, ensuring seamless integration into the U.S. market. In addition, KRTL Biotech excels in client acquisition, sourcing exclusive APIs, and providing strategic regulatory guidance. Their innovative approach to navigating the complexities of pharmaceutical compliance and market entry positions them as a key driver of success for their partners and clients.
Additional information on KRTL is available online atwww.krtlholding.comand www.krtl-icc.com and www.krtlbiotech.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. Words such as "anticipates," "believes," "plans," "expects," "intends," "projects," "estimates," "future," and "opportunity" and similar expressions are used to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance. These risks and uncertainties include, but are not limited to, changes in regulatory requirements, market conditions, and other factors described in the Company's filings. Additional information concerning risks and uncertainties that could materially affect KRTL’s business and financial results is included in the Company’s filings with the OTC Markets and, where applicable, the SEC. You should not place undue reliance on forward-looking statements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.